Home › NDC Lookup › RxCUI directory › RxCUI 2625917

Adagrasib 200 MG Oral Tablet — RxCUI 2625917

RxNorm drug concept · Semantic clinical drug
RxCUI 2625917 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2625917
Official nameAdagrasib 200 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)278 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Adagrasib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Krazati is a targeted therapy — meaning it goes after a specific abnormality in your cancer cells rather than attacking all rapidly dividing cells the way traditional chemotherapy...
  • What exactly is Krazati (adagrasib) and why was it prescribed to me?
  • The most common side effects are nausea, diarrhea, and vomiting — these happen in the vast majority of people taking Krazati. Fatigue, muscle and joint pain, decreased appetite, an...
  • What side effects should I expect, and which ones mean I should call someone right away?
📖 Read our full Adagrasib guide →

🕸️ Concept Web — How Adagrasib 200 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Adagrasib 200 MG Oral Tablet RxCUI 2625917

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Adagrasib 2625882
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Krazati 2625918
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Adagrasib Oral Tablet 2625916
    • Adagrasib Oral Product 2625914
    • Adagrasib Pill 2625915
    • Adagrasib Oral Tablet [Krazati] 2625922
    • Krazati Oral Product 2625920
    • Krazati Pill 2625921
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Adagrasib 200 MG SCDC · 2625913
  • Adagrasib Oral Tablet SCDF · 2625916
  • Adagrasib Oral Product SCDG · 2625914
  • Adagrasib Pill SCDG · 2625915

Brand-Name Concepts

  • Adagrasib 200 MG Oral Tablet [Krazati] SBD · 2625923
  • Adagrasib 200 MG [Krazati] SBDC · 2625919
  • Adagrasib Oral Tablet [Krazati] SBDF · 2625922
  • Krazati Oral Product SBDG · 2625920
  • Krazati Pill SBDG · 2625921
  • Krazati BN · 2625918

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2625917 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
80739-0812-12 1 BOTTLE in 1 CARTON (80739-812-12) / 120 TABLET, COATED in... KRAZATI Mirati Therapeutics, Inc 2022-12-12
80739-0812-18 1 BOTTLE in 1 CARTON (80739-812-18) / 180 TABLET, COATED in... KRAZATI Mirati Therapeutics, Inc 2022-12-12
Observed labelers: Mirati Therapeutics, Inc (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.